Bank of America
KALV

Bank of America’s KalVista Pharmaceuticals KALV Stock Holding History

Bank of America’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Buy
555,628
+165,815
+43% +$2.67M ﹤0.01% 2862
2025
Q4 		$6.3M Buy
389,813
+25,404
+7% +$336K ﹤0.01% 3198
2025
Q3 		$4.44M Sell
364,409
-2,557
-0.7% -$35.3K ﹤0.01% 4131
2025
Q2 		$4.15M Buy
366,966
+58,719
+19% +$718K ﹤0.01% 4091
2025
Q1 		$3.56M Buy
308,247
+198,197
+180% +$2.02M ﹤0.01% 4161
2024
Q4 		$932K Buy
110,050
+57,356
+109% +$594K ﹤0.01% 5085
2024
Q3 		$610K Sell
52,694
-9,813
-16% -$123K ﹤0.01% 5365
2024
Q2 		$736K Buy
62,507
+38,552
+161% +$450K ﹤0.01% 5093
2024
Q1 		$284K Sell
23,955
-8,636
-26% -$115K ﹤0.01% 5690
2023
Q4 		$399K Buy
32,591
+10,130
+45% +$92.2K ﹤0.01% 5650
2023
Q3 		$216K Buy
22,461
+1,414
+7% +$14.4K ﹤0.01% 5864
2023
Q2 		$189K Sell
21,047
-1,787
-8% -$16.5K ﹤0.01% 5870
2023
Q1 		$179K Buy
22,834
+4,986
+28% +$37.2K ﹤0.01% 5981
2022
Q4 		$121K Buy
17,848
+12,082
+210% +$64.7K ﹤0.01% 6161
2022
Q3 		$84K Sell
5,766
-2,071
-26% -$28.9K ﹤0.01% 6425
2022
Q2 		$77K Sell
7,837
-62,231
-89% -$687K ﹤0.01% 6612
2022
Q1 		$1.03M Buy
70,068
+2,717
+4% +$39K ﹤0.01% 5200
2021
Q4 		$891K Buy
67,351
+54,103
+408% +$861K ﹤0.01% 5402
2021
Q3 		$232K Buy
13,248
+1,561
+13% +$31.6K ﹤0.01% 6202
2021
Q2 		$279K Sell
11,687
-7,509
-39% -$196K ﹤0.01% 5843
2021
Q1 		$493K Buy
19,196
+6,009
+46% +$158K ﹤0.01% 5380
2020
Q4 		$250K Sell
13,187
-1,778
-12% -$30.5K ﹤0.01% 5462
2020
Q3 		$189K Sell
14,965
-4,072
-21% -$50.9K ﹤0.01% 5323
2020
Q2 		$231K Sell
19,037
-986
-5% -$10.5K ﹤0.01% 5141
2020
Q1 		$153K Buy
20,023
+15,663
+359% +$211K ﹤0.01% 5262
2019
Q4 		$78K Sell
4,360
-3,315
-43% -$43.3K ﹤0.01% 6098
2019
Q3 		$90K Buy
7,675
+2,569
+50% +$41.5K ﹤0.01% 6096
2019
Q2 		$113K Sell
5,106
-623
-11% -$14.6K ﹤0.01% 5944
2019
Q1 		$164K Buy
5,729
+1,335
+30% +$28.9K ﹤0.01% 5622
2018
Q4 		$87K Buy
4,394
+4,149
+1,693% +$83.4K ﹤0.01% 5989
2018
Q3 		$5K Buy
+245
New +$3.31K ﹤0.01% 6828
2016
Q4 		– Sell
-59
Closed – – 7176
2016
Q3 		$0 Sell
59
-239
-80% -$1.8K ﹤0.01% 7230
2016
Q2 		$3K Buy
+298
New +$3.45K ﹤0.01% 6803
2016
Q1 		– Sell
-21
Closed -$1K – 7163
2015
Q4 		$1K Buy
21
+18
+600% +$942 ﹤0.01% 7190
2015
Q3 		$0 Sell
3
-21
-88% -$1.79K ﹤0.01% 7307
2015
Q2 		$2K Buy
+24
New +$2.38K ﹤0.01% 7046

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America's KALV Position: Q1 2026 in Review

Bank of America increased its KalVista Pharmaceuticals (KALV) stake by 43% in Q1 2026, buying an estimated $2.67M and bringing the position to 555,628 shares worth $11.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2862.

Bank of America first reported a position in KALV in Q2 2015 and has held it in 36 quarters since. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Bank of America held 555,628 shares of KalVista Pharmaceuticals worth $11.2M as of Q1 2026.
  • Bank of America bought 165,815 KalVista Pharmaceuticals shares in Q1 2026, an estimated $2.67M.
  • KalVista Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2862 holding.
  • Bank of America first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 36 quarters since.
  • 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.